Esperion to acquire Corstasis for $75M upfront payment
Source: SeekingAlpha
2026-03-03 06:31:35 ET
More on Esperion Therapeutics
- Esperion Therapeutics: Past The Turnaround, Waiting On Guidelines
- Esperion Therapeutics, Inc. (ESPR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Top Quant rated bullish small cap stocks among companies with high short interest
- Seeking Alpha’s Quant Rating on Esperion Therapeutics
- Historical earnings data for Esperion Therapeutics
Read the full article on Seeking Alpha
For further details see:
Esperion to acquire Corstasis for $75M upfront payment
Esperion Therapeutics Inc.
NASDAQ: ESPR
ESPR Trading
-6.28% G/L:
$2.685 Last:
3,477,657 Volume:
$2.72 Open:
ESPR Latest News
March 05, 2026 07:00:00 am
HLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular Disease
March 03, 2026 06:00:00 am
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst(TM) (bumetanide nasal spray)
February 24, 2026 08:00:00 am
Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10
ESPR Stock Data
$804,448,466
234,999,359
0.16%
70
N/A
Pharmaceuticals
Healthcare
US
Ann Arbor
